PT - JOURNAL ARTICLE AU - Visser, Denise AU - Tuncel, Hayel AU - Ossenkoppele, Rik AU - Yaqub, Maqsood AU - Wolters, Emma E AU - Timmers, Tessa AU - Weltings, Emma AU - Coomans, Emma M AU - Hollander, Marijke den AU - van der Flier, Wiesje M AU - van Berckel, Bart NM AU - Golla, Sandeep SV TI - Longitudinal tau PET using [<sup>18</sup>F]flortaucipir: Comparison of (semi)quantitative parameters AID - 10.1101/2021.08.27.21262740 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.27.21262740 4099 - http://medrxiv.org/content/early/2021/08/30/2021.08.27.21262740.short 4100 - http://medrxiv.org/content/early/2021/08/30/2021.08.27.21262740.full AB - Purpose Semi-quantitative PET measures can be affected by changes in blood flow, whereas quantitative measures are not. The aim of the study was to compare semi-quantitative(SUVr) and quantitative(R1, BPND) parameters of longitudinal tau PET scans with [18F]flortaucipir, with respect to changes in blood flow.Methods Subjects with subjective cognitive decline(SCD; n=38) and Alzheimer’s disease(AD) patients(n=24) underwent baseline(BL) and 2-year follow-up(FU) dynamic [18F]flortaucipir PET scans. BPND and R1 were estimated using RPM and SUVr(80-100min) was calculated (cerebellar gray as reference). For each region-of-interest ((trans)entorhinal, limbic and neocortical) and parameter, %change was calculated. Regional SUVrs were compared to corresponding DVR (= BPND+1) using paired T-tests. Additionally, simulations were performed to model effects of flow changes on BPND and SUVr in different binding categories. Thereafter, %bias for SUVr with respect to underlying binding and flow were evaluated.Results In SCD, there was a difference between %change in the (trans)entorhinal ROI (DVR 2.56% vs SUVr 1.85%) only. In AD, a difference was found in the limbic ROI (DVR 6.61% vs SUVr 7.52%) only. R1 changes were small(+0.7% in SCD and -1.6% in AD). Simulations illustrated with increasing flow a decreased %bias for SUVr in low binding conditions, whereas a slightly increased bias was observed in high binding conditions.Conclusion SUVr provided an accurate estimate of specific binding for [18F]flortaucipir over a two-year follow-up. However, simulations showed that flow changes can affect [18F]flortaucipir SUVr, hence DVR/BPND should be preferred in more advanced disease stages and/or conditions that could induce significant flow changes like pharmacotherapeutic interventions.Competing Interest StatementVisser, Tuncel, Ossenkoppele, Yaqub, Wolters, Timmers, Weltings, Coomans, Den Hollander, Boellaard, and Golla declares that he/she has no conflict of interest. Van der Flier received grant support from ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Stichting Dioraphte, Gieskes-Strijbis Fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, Combinostics. All funding is paid to the institution. WvdF holds the Pasman chair. Van Berckel received research support from ZonMW, AVID radiopharmaceuticals, CTMM and Janssen Pharmaceuticals. He is a trainer for Piramal and GE. He receives no personal honoraria. No other potential conflicts of interest relevant to this article exist. Funding StatementThis research was funded by a ZonMW Memorabel grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Medical Ethics Review Committee of the Amsterdam UMC VU Medical center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data used in the present study may be available upon request to the corresponding author.